Status:
TERMINATED
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Ichthyosis
Eligibility:
All Genders
12-75 years
Phase:
PHASE2
Brief Summary
Efficacy and Safety of imsidolimab in Participants with Ichthyosis
Detailed Description
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of imsidolimab compared with placebo in adolescent and adult parti...
Eligibility Criteria
Inclusion
- Diagnosis of Ichthyosis
- IASI total score ≥ 18, erythema score ≥ 2
- Participant has been using emollient daily for at least 1 week prior to Day 1 and agrees to continue using that same emollient daily at the same frequency throughout the study
Exclusion
- A participant with ichthyosis vulgaris, X-linked ichthyosis, or lamellar ichthyosis will be excluded.
Key Trial Info
Start Date :
January 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 19 2021
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04697056
Start Date
January 25 2021
End Date
November 19 2021
Last Update
September 16 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 106
Palo Alto, California, United States, 94304
2
Site 104
New Haven, Connecticut, United States, 06519
3
Site 112
Miami, Florida, United States, 33125
4
Site 101
Chicago, Illinois, United States, 60611